Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VTYX vs GLUE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VTYX Captures Overall Composite Edge (50.4 HOLD vs 44.2 HOLD), While GLUE Leads 3–2 on Growth & Valuation Pillars

VTYX Overall Winner 6-Pillar Tally: VTYX 2 – 3 GLUE (1 Tie) Matrix Metrics: VTYX 6 – 4 GLUE

As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Monte Rosa Therapeutics, Inc. (GLUE) on higher Unified Composite conviction (50.4/100 HOLD vs. 44.2/100 HOLD) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while GLUE wins 3–2 across the 6-pillar growth and valuation breakdown. VTYX trades at $14.00 (N/M Forward P/E, 0.0% operating margin) versus GLUE at $9.18 (10.0x Forward P/E, -214.5% operating margin).

  • Growth vs. Quality Trade-Off: VTYX earns the overall head-to-head edge with a stronger Unified Composite Score (50.4/100 HOLD vs. GLUE 44.2/100 HOLD) and 2.07β · 2% Vol risk profile, whereas GLUE leads top-line expansion (+325.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VTYX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.7); meanwhile GLUE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTYX vs GLUE
VTYX NASDAQ Head-to-Head Winner
Ventyx Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$14.00
+0.14% 1D
Market Cap $1.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.07β · 2% Vol
Unified Composite Score
50.4 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (19.0% over 20 days), RSI 71
RSI-14: 70.7 · SMA20: $13.96 · SMA50: $12.72
GLUE NASDAQ
Monte Rosa Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.18
-2.03% 1D
Market Cap $795.5M
TTM Revenue $70M
Forward P/E 10.0x
Beta / 30D Vol 0.95β · 53% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 32.0 Fund 51.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.2%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $10.50 · SMA50: $11.21

6-Pillar Scorecard Institutional Category Breakdown (VTYX 2 – 3 GLUE)

Columns: Metric · VTYX · GLUE
1. Valuation Multiples GLUE
Forward P/E N/M 10.0x
Trailing P/E N/M 10.0x
PEG Ratio N/M N/M
EV / Revenue N/M 11.2x
2. Growth & Scale GLUE
Revenue Growth (YoY) +0.0% +325.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $70M
Market Cap $1.0B $795.5M
3. Profitability & Quality VTYX
Gross Margin N/A -92.2%
Operating Margin 0.0% -214.5%
Net Profit Margin 0.0% -186.2%
Return on Equity (ROE) -45.4% -35.3%
4. Balance Sheet & Cash Flow GLUE
Cash Generation (TTM) N/A -$174M
Cash Flow Margin N/A N/A
Net Cash / Leverage $2.68 Book/Sh · -45.4% ROE $8.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VTYX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 0.5% (<1st %ile) 100.8% (16th %ile)
Put/Call OI Skew N/A 6.27x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTYX (6) vs GLUE (4)
Institutional Metric VTYX GLUE Criterion Row Edge
Market Capitalization
Scale
$1.0B $795.5M Larger Scale VTYX
Trailing P/E Ratio
Valuation
N/M 10.0x Lower Multiple GLUE
Forward P/E Ratio
Valuation
N/M 10.0x Lower Multiple GLUE
Revenue Growth (YoY)
Growth
+0.0% +325.8% Higher Growth GLUE
Operating Margin (TTM)
Profitability
0.0% -214.5% Higher Margin VTYX
Net Profit Margin
Profitability
0.0% -186.2% Higher Margin VTYX
Return on Equity (ROE)
Capital Efficiency
-45.4% -35.3% Higher ROE GLUE
52-Week Range Position
Momentum
55% ($1–$25) 1% ($9–$26) Stronger Trend VTYX
Beta / 30D Volatility
Risk Regime
2.07β · 2% Vol 0.95β · 53% Vol Lower Realized Risk VTYX
Unified Institutional Score
Composite Signal
50.4 / 100 (HOLD) 44.2 / 100 (HOLD) Higher Composite VTYX
Trailing 12M Revenue (USD)
Operating Scale
N/A $70M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -92.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 11.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($2.68 Book/Sh · -45.4% ROE) -$174M ($8.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VTYX +12.84 pp
VTYX: +0.36% · GLUE: -12.48%
3M Horizon VTYX +28.93 pp
VTYX: +40.0% · GLUE: +11.07%
6M Horizon VTYX +21.18 pp
VTYX: +46.6% · GLUE: +25.42%
1Y Horizon VTYX +21.18 pp
VTYX: +46.6% · GLUE: +25.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTYX vs GLUE. Trailing 12-month operating profitability (VTYX 0.0% vs GLUE -214.5%) and valuation multiples (VTYX N/M vs GLUE 10.0x Forward P/E) are benchmarked directly in Pillar 4 below.

VTYX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-45.4% · N/M
GLUE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$70M
Gross Margin-92.2%
Op. Margin-214.5%
ROE / Fwd P/E-35.3% · 10.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTYX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.5%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTYX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GLUE BREAKDOWN
85d in phase · OBV DISTRIBUTION
Current IV 100.8%
IV Percentile 16th %ile
Put/Call OI Skew 6.27x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact GLUE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTYX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GLUE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $795.5M market capitalization and -214.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VTYX vs GLUE Key Questions & Quantitative Answers

As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Monte Rosa Therapeutics, Inc. (GLUE) on higher Unified Composite conviction (50.4/100 HOLD vs. 44.2/100 HOLD) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while GLUE wins 3–2 across the 6-pillar growth and valuation breakdown. VTYX trades at $14.00 (N/M Forward P/E, 0.0% operating margin) versus GLUE at $9.18 (10.0x Forward P/E, -214.5% operating margin). Growth vs. Quality Trade-Off: VTYX earns the overall head-to-head edge with a stronger Unified Composite Score (50.4/100 HOLD vs. GLUE 44.2/100 HOLD) and 2.07β · 2% Vol risk profile, whereas GLUE leads top-line expansion (+325.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VTYX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.7); meanwhile GLUE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GLUE leads the Growth & Scale pillar: VTYX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with GLUE at +325.8% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (-92.2% gross margin, -214.5% operating margin). On trailing 12-month operating scale, VTYX generates N/A in USD-normalized revenue versus $70M for GLUE. In operating R&D and SG&A reinvestment, VTYX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GLUE.

GLUE screens cheaper on headline valuation multiples. VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GLUE trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 11.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTYX (-45.4% ROE) versus GLUE (-35.3% ROE) capital efficiency.

In options market volatility and institutional positioning, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk). By comparison, GLUE carries 100.8% implied volatility (16th %ile, Compressed (<25th %ile)), a 6.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.95β · 53% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.